Table III.
The use of drugs considered a priori to be potentially related to increased risk of GI bleeding.
| Drug | % AUGIB (n = 156) |
% Control group (n = 312) |
p-value |
|---|---|---|---|
| NSAIDs | 20% (31) | 8% (24) | 0.0002 |
| NSAIDs + LDA | 8% (13) | 1% (4) | 0.0003 |
| Warfarin | 15% (23) | 7% (21) | 0.0069 |
| LDA | 40% (62) | 30% (93) | 0.0371 |
| LDA + SSRIs | 8% (12) | 3% (9) | 0.0302 |
| Warfarin + SSRIs | 3% (4) | 0% (1) | 0.0444 |
| PPIs | 40% (62) | 49% (152) | NS |
| NSAIDs + PPIs | 8% (13) | 4% (14) | NS |
| SSRI drugs | 16% (25) | 12% (37) | NS |
| Platelet inhibitors1 | 7% (11) | 5% (16) | NS |
| Bisphosphonate drugs | 4% (7) | 3% (10) | NS |
| LMWH/Heparin | 5% (8) | 4% (11) | NS |
| Corticosteroids | 3% (5) | 3% (8) | NS |
| LDA + warfarin | 4% (6) | 2% (7) | NS |
| NSAIDs + warfarin | 3% (4) | 1% (3) | NS |
| NSAIDs + SSRI | 3% (5) | 1% (3) | NS |
| Platelet inhibitors + SSRIs | 2% (3) | 1% (2) | NS |
Abbreviations: LDA = low-dose aspirin; LMWH = low-molecular-weight heparin; NSAIDs = non-steroidal anti-inflammatory drugs; PPIs = proton pump inhibitors; SSRIs = selective serotonin receptor antagonists; NS = Not significant.
1Platelet inhibitors included were: clopidogrel, prasugrel, dipyridamole and ticlopidine.